{"url_path":"/sec/ino/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1055726/0001055726-26-000019-index.html","accession_number":"0001055726-26-000019","cik":"0001055726","ticker":"INO","issuer_name":"INOVIO PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1055726/0001055726-26-000019-index.html","primary_entity_key":"0001055726","primary_entity_name":"INOVIO PHARMACEUTICALS, INC."},"word_count":75,"has_tables":true,"body_markdown":"Item 9.01    Financial Statements and Exhibits.\n\n(d) Exhibits\n\nExhibit Number\n\n[99.1](ino-33126x8kex991.htm)\n\n[Press Release, dated May 13, 2026 (filed herewith)](ino-33126x8kex991.htm)\n\n104Cover Page Interactive Data File (formatted as inline XBRL).\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n  INOVIO PHARMACEUTICALS, INC.\n\nDate: May 13, 2026  By: /s/ Peter Kies\n\n   Peter Kies\n\n   Chief Financial Officer"}